Polaryx Therapeutics, Inc. (NasdaqCM: PLYX)
Health Care · Pharmaceuticals · US
$2.00
-3.85% today · -94.1% 1Y
Polaryx Therapeutics, Inc. (NasdaqCM: PLYX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $103.68M and employs 11 people.
Over the last twelve months the share price has lost 94.1%, trading between 1.85 and 48.91.
Tweenvest scores Polaryx Therapeutics, Inc. across four factors: quality 44/100, value 65/100. Its strongest factor is value.
PLYX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $103.68M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.15
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $48.91
- 52-week low
- $1.85
- Avg volume (3M)
- —
- Shares outstanding
- 49.85M
- Employees
- 11
- Next earnings
- —
About Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
- ISIN
- US73110F1003
- Founded
- 2014
- Listed since
- Feb 2, 2026
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Cumberland Pharmaceuticals Inc.NasdaqGS: CPIX | $104.58M | $6.98 | +1.31% |
| Vita Life Sciences LimitedASX: VLS | $104.53M | AU$2.78 | -0.71% |
| SYN-TECH Chem. & Pharm. Co., Ltd.TPEX: 1777 | $104.15M | NT$74.40 | +0.13% |
| Medexus Pharmaceuticals Inc.TSX: MDP | $104.05M | CA$4.72 | -7.81% |
| Semnur Pharmaceuticals, Inc.OTCPK: SMNR | $103.59M | $0.45 | -24.87% |
| Aardvark Therapeutics, Inc.NasdaqGS: AARD | $103.08M | $4.71 | -5.04% |
| October Pharma S.A.ECASE: OCPH | $102.66M | EGP223.92 | -0.76% |
| Stablecoin Development CorporationNYSEAM: SDEV | $100.72M | $1.99 | -28.42% |
Figures last refreshed Oct 4, 2026.